Intraurethral prostaglandin improves quality of vacuum erection therapy.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 8647152.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The aim of this study was to investigate whether intraurethral prostaglandin E1 (PGE1) improves vacuum-induced penile rigidity. Nineteen patients with a mean age of 55 years (range 30-66 years) complaining of erectile dysfunction for 24 months (range 3-156 months) were investigated. The penile diameter was measured and a mark was made 50 mm proximal of the coronary sulcus on the flaccid penis. Twenty micrograms of liquid PGE1 (pH 4.5; 308 mosm/l) were instilled intraurethrally; thereafter the meatus was occluded for 10 min. Penile diameter and increase in length of the initially 50-mm line were measured with both pure vacuum-induced erection as well as combined with PGE1. The vacuum erection device alone lengthened the distance by 26 mm (range 18-64 mm) and the diameter by 4 mm (range 2-10 mm). Combined with PGE1, 36 mm (range 27-70 mm; p = 0.016) and 7 mm (range 2-11 mm; p = 0.04) were found, respectively. We conclude that PGE1 significantly increases vacuum-induced tumescence. Optimized pharmacological preparations for intraurethral application are a new way to further improve vacuum-assisted erection.
Medical subject headings
- Alprostadil
- Erectile Dysfunction
- Penile Erection
- Vasodilator Agents